A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab
Maria Rosario(Millennium Engineering and Integration (United States)), Irving H. Fox(Takeda (United States)), Michael Bargfrede(Takeda (United States)), Nathanael L. Dirks(Metrum Research Group (United States)), Asit Parikh, Catherine Milch(Millennium Engineering and Integration (United States)), Tim Wyant(Curis (United States)), Eric R. Fedyk(Takeda (United States))
Cited by 158
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
|Gastroenterology|2014|714
Treatment of Ulcerative Colitis with a Humanized Antibody to the α <sub>4</sub> β <sub>7</sub> Integrin
|New England Journal of Medicine|2005|694